Enviro Infra Engineers secures Rs 400 crore ZLD CETP order from MIDC, enters advanced wastewater treatment space
Enviro Infra Engineers Limited (EIEL) announced a major breakthrough on July 10, 2025, with the receipt of a ₹400 crore project from Maharashtra Industrial Development Corporation (MIDC), marking its foray into the Zero Liquid Discharge (ZLD) segment.
The prestigious project is aimed at upgrading the Common Effluent Treatment Plants (CETPs) in the cooperative industrial estates of Ichalkaranji, Hatkanangale, and Yadrav in Kolhapur district to prevent pollution of the Panchganga River.
The scope of the 24-month project includes design, supply, construction, installation, testing, commissioning, and operations & maintenance of advanced ZLD CETPs featuring technologies such as ultrafiltration, reverse osmosis, and multiple vapor recompression (MVR).
Chairman Sanjay Jain commented, 'This project represents a pivotal moment for EIEL, demonstrating our engineering capabilities and expanding our presence in Maharashtra. We are proud to contribute to restoring the Panchganga River with this environmentally significant assignment.'
With this order, EIEL strengthens its position as a leading EPC player in water and wastewater solutions, aligned with India's sustainability and environmental goals.
Enviro Infra Engineers is a national player in water and wastewater treatment plants and supply schemes for government agencies, backed by an in-house engineering and construction team, along with operations and maintenance expertise.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Why Dr. Reddy's shares are down nearly 2% today? Explained
By Aditya Bhagchandani Published on July 31, 2025, 09:44 IST Shares of Dr. Reddy's Laboratories Ltd dropped nearly 2% to ₹1,269.70 in early trade on Wednesday, reacting sharply to the overnight announcement by former U.S. President Donald Trump regarding the imposition of 25% tariffs on Indian exports to the United States. The move includes a yet-unspecified penalty for India's continued energy and defense dealings with Russia. The stock was among the worst-hit in the pharmaceutical space as investors digested the potential impact on generic drug exports, which constitute a major portion of India's pharmaceutical trade with the U.S. Pharma Exports at Risk? The United States is a critical market for Indian drugmakers. In fact, Dr. Reddy's derives 46% of its revenue from the U.S., making it highly sensitive to any changes in trade policy. While pharmaceuticals are currently exempt from the reciprocal tariff list (announced in April), officials from the White House confirmed to CNBC-TV18 that these exemptions may soon be lifted. The Department of Commerce's Section 232 investigation into Indian generic drug exports has now concluded, and according to Trump's latest statement, tariffs on pharma 'are coming soon.' Currently, India pays zero tariffs on generic drug exports to the U.S. If the proposed 25% tariff is applied to this sector, Indian companies may have to choose between: Passing the cost onto U.S. consumers , making Indian generics less price-competitive Reevaluating U.S. portfolios , withdrawing lower-margin or loss-making products Manufacturing in the U.S., which may offer no cost advantage for generics Broader Impact Across the Pharma Space Besides Dr. Reddy's, stocks likely to remain under pressure include: Sun Pharma (33% U.S. exposure) Aurobindo Pharma (45%) Gland Pharma (53%) Divi's Laboratories Cipla, Lupin, and Biocon Who Might Buck the Trend? Pharma firms and healthcare providers with a domestic business focus or minimal U.S. exposure may remain resilient: Ajanta Pharma, Eris Lifesciences, Torrent Pharma Apollo Hospitals, Fortis Healthcare, Aster DM Diagnostics players like Dr. Lal Pathlabs, Metropolis Final Word Though Indian pharma exports are not yet officially included in the tariff list, Trump's statements have created uncertainty for the sector. Until there is clarity from the U.S. Trade Representative or India's Commerce Ministry, investor sentiment around high U.S.-exposed pharma names may remain volatile. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
3 hours ago
- Business Upturn
Gokaldas Exports crashes 6% after Trump's 25% tariff announcement on India
By Aditya Bhagchandani Published on July 31, 2025, 09:55 IST Shares of Gokaldas Exports Ltd tanked 6.2% to ₹834.90 on Wednesday, July 31, following U.S. President Donald Trump's announcement of a 25% tariff on Indian exports starting August 1. The steep drop follows a broader sell-off in Indian textile exporters with high U.S. revenue exposure. The announcement, which also included a penalty on India for purchasing Russian oil, triggered a decline across key players in the textile space. Alongside Gokaldas, stocks of Welspun Living, Indo Count Industries, and Pearl Global fell by up to 7%. U.S. Market Exposure Driving the Sell-Off: Gokaldas Exports: ~70% of revenue from U.S. ~70% of revenue from U.S. Indo Count Industries: ~70% U.S. exposure ~70% U.S. exposure Welspun Living: ~65% ~65% Pearl Global: ~50% ~50% Arvind Ltd: ~30% ~30% KPR Mill: ~21% The textile sector is under pressure as the new tariffs would push total duty costs for Indian apparel exporters to well over 30%, considering existing U.S. duties of 15–18% on such products. Sivaramakrishnan Ganapathi, Managing Director of Gokaldas Exports, earlier stated that price hikes to offset tariffs may impact demand in the U.S. market. India currently holds a 6% share of the U.S. readymade garment import market, compared to 19% for Vietnam and 9% for Bangladesh. With Vietnam agreeing to a 20% tariff and Bangladesh already facing a 35% duty, India's 25% rate places it at a competitive disadvantage. Analysts warn of potential order slowdowns and pricing pressure in the coming quarters for export-heavy Indian garment companies. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
3 hours ago
- Business Upturn
Why are Waaree Energies shares down nearly 5% today? Explained
By Aditya Bhagchandani Published on July 31, 2025, 09:42 IST Shares of Waaree Energies Ltd dropped 4.67% to ₹2,996.80 in early trade on Wednesday, making it one of the top losers on the NSE. The sharp decline comes amid fresh concerns over U.S. trade relations after former U.S. President Donald Trump announced a 25% tariff on Indian exports, coupled with a penalty for the country's continued purchase of oil and military equipment from Russia. The market reacted swiftly, especially for companies like Waaree Energies, which have significant revenue exposure to the United States. According to recent data, 57% of Waaree's revenue comes from the U.S., making it one of the most vulnerable firms if tariffs are implemented. What Triggered the Fall? Trump's post, made Tuesday evening on Truth Social, stated: 'INDIA WILL THEREFORE BE PAYING A TARIFF OF 25%, PLUS A PENALTY… STARTING ON AUGUST FIRST.' This announcement has spooked investors in export-heavy sectors, particularly solar energy, where Indian companies like Waaree dominate U.S. supply chains. The U.S. remains one of the largest markets for solar panel imports, most of which come from overseas. If the new tariffs take effect, they could severely impact Waaree's export margins and competitiveness, potentially leading to lower profitability or loss of market share in the world's second-largest solar energy market. Broader Impact on Indian Companies with High U.S. Exposure Waaree isn't alone. Other Indian companies with heavy U.S. revenue exposure also face downside risks, including: Mphasis (80%) Birlasoft (85.5%) Infosys (62%) TCS, Wipro, HCLTech (all 50%+) Gland Pharma (53%) Dr. Reddy's, Aurobindo, Sun Pharma Arvind (51%) Sona BLW, Bharat Forge Although Trump's post was later deleted from X (formerly Twitter), the policy stands firm on Truth Social, and the August 1 deadline remains intact, as reiterated in a follow-up message. Investor Outlook Until there is official clarification from the U.S. administration or the Indian government, shares of high U.S.-exposed companies—especially exporters like Waaree Energies—may remain under pressure. Investors are advised to monitor geopolitical developments and await further trade policy details, especially regarding potential exemptions or bilateral talks between New Delhi and Washington. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
